drugset / Trial / NCT00927784
Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD
Phase 2
Terminated
10 enrolled
Icahn School of Medicine at Mount Sinai
Angioblast Systems · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Left ventricular assist devices (LVADs) are one treatment option for people with congestive heart failure. This study will evaluate the safety of injecting mesenchymal precursor cells (MPCs) into the heart during LVAD implantation surgery and examine if injecting MPCs into the heart is effective at improving heart function.
Timeline
- Start
- 2009-08
- Primary completion
- 2010-05
- Completion
- 2011-02
Outcome
Outcome not reported
Stopped (Enrollment): “The enrollment has been terminated by the NHLBI for administrative reasons.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RevascorTM | Cell therapy | 25 cells | Other |
| Subject | RevascorTM | Cell therapy | 75 cells | Other |